Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Salah, Ghabri"'
Autor:
Salah Ghabri
Publikováno v:
Value in Health. 26:447-448
Autor:
Olena Mandrik, Tim Mathes, Luke Vale, Ariel Bardach, Torbjørn Wisløff, Salah Ghabri, Candyce Hamel, Jeremy D. Goldhaber-Fiebert, J L Hans Severens
Publikováno v:
Value in Health, 24(4), 463-472. Elsevier Ltd.
Publikováno v:
Applied Health Economics and Health Policy
Applied Health Economics and Health Policy, Adis, 2020, 18 (4), pp.491-508. ⟨10.1007/s40258-020-00562-z⟩
Applied Health Economics and Health Policy, Adis, 2020, 18 (4), pp.491-508. ⟨10.1007/s40258-020-00562-z⟩
International audience; Background: Oncology is among the most active therapeutic fields in terms of new drug development projects, with increasingly expensive drugs. The expected clinical benefit and cost effectiveness of these treatments in clinica
Autor:
Lotte Maria Gertruda Steuten, Gillian Sanders Schmidler, Claire Rothery, Anirban Basu, Salah Ghabri, Mark Strong, Hendrik Koffijberg, Saskia Knies, Elisabeth Fenwick, James F. Murray
Publikováno v:
Value in Health, 23(2), 139-150. Elsevier Ltd.
Value in health, 23(2), 139-150. Elsevier
Value in health, 23(2), 139-150. Elsevier
Healthcare resource allocation decisions made under conditions of uncertainty may turn out to be suboptimal. In a resource constrained system in which there is a fixed budget, these suboptimal decisions will result in health loss. Consequently, there
Publikováno v:
PharmacoEconomics, 40(3), 241-248
PharmacoEconomics 40 (2022) 3
PharmacoEconomics 40 (2022) 3
Health care decision makers in many jurisdictions use cost-effectiveness analysis based on health economic decision models for policy decisions regarding coverage and price negotiation for medicines and medical devices. While validation of health eco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2a3a73289062e700adcbe6b7d4e826d
http://hdl.handle.net/10029/625435
http://hdl.handle.net/10029/625435
Publikováno v:
PharmacoEconomics
PharmacoEconomics, Springer Verlag, 2020, 38 (5), pp.459-471. ⟨10.1007/s40273-020-00887-6⟩
PharmacoEconomics, Springer Verlag, 2020, 38 (5), pp.459-471. ⟨10.1007/s40273-020-00887-6⟩
This systematic literature review (SLR) had two objectives: to analyse published economic evaluations of biological disease-modifying anti-rheumatic drugs (bDMARDs) for patients with moderate to severe rheumatoid arthritis (RA) previously treated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e9a267853c92bd698a4b87867afc9bb
https://hal.archives-ouvertes.fr/hal-03355657
https://hal.archives-ouvertes.fr/hal-03355657
Autor:
Elisabeth Fenwick, Mark Strong, Anirban Basu, Salah Ghabri, Lotte Maria Gertruda Steuten, James F. Murray, Gillian Sanders Schmidler, Claire Rothery, Saskia Knies, Hendrik Koffijberg
Publikováno v:
Value in Health, 23(3), 277-286. Elsevier Ltd.
Value in health, 23(3), 277-286. Elsevier
Value Health
Value in health, 23(3), 277-286. Elsevier
Value Health
The allocation of health care resources among competing priorities requires an assessment of the expected costs and health effects of investing resources in the activities, and on the opportunity cost of the expenditure. To date, much effort has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcaaadebd149be3d91daa3c4ce98602d
https://pure.eur.nl/en/publications/41be1d8b-5b5e-4bd4-9b80-1c455e02c70b
https://pure.eur.nl/en/publications/41be1d8b-5b5e-4bd4-9b80-1c455e02c70b
Autor:
Caecilia Schmid, Andrea Kuemmerle, Johannes Blum, Salah Ghabri, Victor Kande, Wilfried Mutombo, Medard Ilunga, Ismael Lumpungu, Sylvain Mutanda, Pathou Nganzobo, Digas Tete, Nono Mubwa, Mays Kisala, Severine Blesson, Olaf Valverde Mordt
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 6, Iss 11, p e1920 (2012)
Trypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2(nd) stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and insuffici
Externí odkaz:
https://doaj.org/article/988bd6a015d74696a5293d47b2c7b000
Publikováno v:
PharmacoEconomics. 37:1-6
Models have become a nearly essential component of health technology assessment. This is because the efficacy and safety data available from clinical trials are insufficient to provide the required estimates of impact of new interventions over long p
Publikováno v:
PharmacoEconomics
PharmacoEconomics, Springer Verlag, 2019, 37 (12), pp.1417-1419. ⟨10.1007/s40273-019-00846-w⟩
PharmacoEconomics, 2019, 37 (12), pp.1417-1419. ⟨10.1007/s40273-019-00846-w⟩
PharmacoEconomics, Springer Verlag, 2019, 37 (12), pp.1417-1419. ⟨10.1007/s40273-019-00846-w⟩
PharmacoEconomics, 2019, 37 (12), pp.1417-1419. ⟨10.1007/s40273-019-00846-w⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::441875c3ba374b6fc512568e5078a0fe
https://halshs.archives-ouvertes.fr/halshs-02319704
https://halshs.archives-ouvertes.fr/halshs-02319704